• Je něco špatně v tomto záznamu ?

Biomarkers in Czech workers exposed to 1,3-butadiene: a transitional epidemiologic study

RJ. Albertini, RJ. Srám, PM. Vacek, J. Lynch, JA. Nicklas, NJ. van Sittert, PJ. Boogaard, RF. Henderson, JA. Swenberg, AD. Tates, JB. Ward, M. Wright, MM. Ammenheuser, B. Binkova, W. Blackwell, FA. de Zwart, D. Krako, J. Krone, H. Megens, P....

. 2003 ; (116) : 1-141; discussion 143-162. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.

Perzistentní odkaz   https://www.medvik.cz/link/bmc20013909

Grantová podpora
P30CA22435 NCI NIH HHS - United States

A multiinstitutional, transitional epidemiologic study was conducted with a worker population in the Czech Republic to evaluate the utility of a continuum of non-disease biological responses as biomarkers of exposure to 1,3-butadiene (BD)* in an industrial setting. The study site included two BD facilities in the Czech Republic. Institutions that collaborated in the study were the University of Vermont (Burlington, Vermont, USA); the Laboratory of Genetic Ecotoxicology (Prague, the Czech Republic); Shell International Chemicals, BV (Amsterdam, The Netherlands); the University of North Carolina at Chapel Hill (Chapel Hill, North Carolina, USA); University of Texas Medical Branch at Galveston (Galveston, Texas, USA); Leiden University (Leiden, The Netherlands); and the Health and Safety Laboratory (Sheffield, United Kingdom). Male volunteer workers (83) participated in the study: 24 were engaged in BD monomer production, 34 in polymerization activities, and 25 plant administrative workers served as unexposed control subjects. The BD concentrations experienced by each exposed worker were measured by personal monitor on approximately ten separate occasions for 8-hour workshifts over a 60-day exposure assessment period before biological samples were collected. Coexposures to styrene, benzene, and toluene were also measured. The administrative control workers were considered to be a homogeneous, unexposed group for whom a series of 28 random BD measurements were taken during the exposure assessment period. Questionnaires were administered in Czech to all participants. At the end of the exposure assessment period, blood and urine samples were collected at the plant; samples were. fractionated, cryopreserved, and kept frozen in Prague until they were shipped to the appropriate laboratories for specific biomarker analysis. The following biomarkers were analyzed: * polymorphisms in genes involved in BD metabolism (Prague and Burlington); * urinary concentrations of 1-hydroxy-2-(N-acetylcysteinyl)-3-butene and 2-hydroxy-1-(N-acetylcysteinyl)-3-butene (M2 [refers to an isomeric mixture of both forms]) (Amsterdam); * urinary concentrations of 1,2-dihydroxy-4-(N-acetylcysteinyl)-butane (M1) (Amsterdam); * concentrations of the hemoglobin (Hb) adducts N-(1-[hydroxymethyl]-2-propenyl)valine and N-(2-hydroxy-3-butenyl)valine (HBVal [refers to an isomeric mixture of both forms]) (Amsterdam); * concentrations of the Hb adduct N-(2,3,4-trihydroxybutyl)valine (THBVal) (Chapel Hill); * T cell mutations in the hypoxanthine phosphoribosyltransferase (HPRT) gene (autoradiographic assay in Galveston with slide review in Burlington; cloning assay in Leiden with mutational spectra determined in Burlington); and * chromosomal aberrations by the conventional method and by fluorescence in situ hybridization [FISH]), and cytogenetic changes (sister chromatid exchanges [SCEs] (Prague). All assay analysts were blinded to worker and sample identity and remained so until all work in that laboratory had been completed and reported. Assay results were sent to the Biometry Facility in Burlington for statistical analyses. Analysis of questionnaire data revealed that the three exposure groups were balanced with respect to age and years of residence in the district, but the control group had significantly more education than the other two groups and included fewer smokers. Group average BD exposures were 0.023 mg/m3 (0.010 ppm) for the control group, 0.642 mg/m3 (0.290 ppm) for the monomer group, and 1.794 mg/m3 (0.812 ppm) for the polymer group; exposure levels showed considerable variability between and within individuals. Styrene exposures were significantly higher in the polymer group than in the other two groups. We found no statistically significant differences in the distributions of metabolic genotypes over the three exposure groups; genotype frequencies were consistent with those previously reported for this ethnic and national population. Although some specific genotypes were associated with quantitative differences in urinary metabolite concentrations or Hb adduct dose-response characteristics, none indicated a heightened susceptibility to BD. Concentrations of both the M2 and M1 urinary metabolites and both the HBVal and THBVal Hb adducts were significantly correlated with group and individual mean BD exposure levels; the Hb adducts were more strongly correlated than the urinary metabolites. By contrast, no significant relations were observed between BD exposures and HPRT gene mutations (whether determined by the auto-radiographic or the cloning method) or any of the cytogenetic biomarkers (whether determined by the conventional method or FISH analysis). Neither the mutational nor the cytogenetic responses showed any association with genotypes. The molecular spectrum of HPRT mutations in BD-exposed workers showed a high frequency of deletions; but the same result was found in the unexposed control subjects, which suggests that these were not due to BD exposure. This lack of association between BD exposures and genetic effects persisted even when control subjects were excluded from the analyses or when we conducted regression analyses of individual workers exposed to different levels of BD.

000      
00000naa a2200000 a 4500
001      
bmc20013909
003      
CZ-PrNML
005      
20200915104413.0
007      
ta
008      
200911s2003 xxu f 000 0|eng||
009      
AR
035    __
$a (PubMed)12931846
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Albertini, Richard J $u Genetic Toxicology Laboratory, University of Vermont, 655 Spear Street, Building C, Burlington VT 05405, USA. Richard.Albertini@uvm.edu
245    10
$a Biomarkers in Czech workers exposed to 1,3-butadiene: a transitional epidemiologic study / $c RJ. Albertini, RJ. Srám, PM. Vacek, J. Lynch, JA. Nicklas, NJ. van Sittert, PJ. Boogaard, RF. Henderson, JA. Swenberg, AD. Tates, JB. Ward, M. Wright, MM. Ammenheuser, B. Binkova, W. Blackwell, FA. de Zwart, D. Krako, J. Krone, H. Megens, P. Musilová, G. Rajská, A. Ranasinghe, JI. Rosenblatt, P. Rössner, J. Rubes, L. Sullivan, P. Upton, AH. Zwinderman,
520    9_
$a A multiinstitutional, transitional epidemiologic study was conducted with a worker population in the Czech Republic to evaluate the utility of a continuum of non-disease biological responses as biomarkers of exposure to 1,3-butadiene (BD)* in an industrial setting. The study site included two BD facilities in the Czech Republic. Institutions that collaborated in the study were the University of Vermont (Burlington, Vermont, USA); the Laboratory of Genetic Ecotoxicology (Prague, the Czech Republic); Shell International Chemicals, BV (Amsterdam, The Netherlands); the University of North Carolina at Chapel Hill (Chapel Hill, North Carolina, USA); University of Texas Medical Branch at Galveston (Galveston, Texas, USA); Leiden University (Leiden, The Netherlands); and the Health and Safety Laboratory (Sheffield, United Kingdom). Male volunteer workers (83) participated in the study: 24 were engaged in BD monomer production, 34 in polymerization activities, and 25 plant administrative workers served as unexposed control subjects. The BD concentrations experienced by each exposed worker were measured by personal monitor on approximately ten separate occasions for 8-hour workshifts over a 60-day exposure assessment period before biological samples were collected. Coexposures to styrene, benzene, and toluene were also measured. The administrative control workers were considered to be a homogeneous, unexposed group for whom a series of 28 random BD measurements were taken during the exposure assessment period. Questionnaires were administered in Czech to all participants. At the end of the exposure assessment period, blood and urine samples were collected at the plant; samples were. fractionated, cryopreserved, and kept frozen in Prague until they were shipped to the appropriate laboratories for specific biomarker analysis. The following biomarkers were analyzed: * polymorphisms in genes involved in BD metabolism (Prague and Burlington); * urinary concentrations of 1-hydroxy-2-(N-acetylcysteinyl)-3-butene and 2-hydroxy-1-(N-acetylcysteinyl)-3-butene (M2 [refers to an isomeric mixture of both forms]) (Amsterdam); * urinary concentrations of 1,2-dihydroxy-4-(N-acetylcysteinyl)-butane (M1) (Amsterdam); * concentrations of the hemoglobin (Hb) adducts N-(1-[hydroxymethyl]-2-propenyl)valine and N-(2-hydroxy-3-butenyl)valine (HBVal [refers to an isomeric mixture of both forms]) (Amsterdam); * concentrations of the Hb adduct N-(2,3,4-trihydroxybutyl)valine (THBVal) (Chapel Hill); * T cell mutations in the hypoxanthine phosphoribosyltransferase (HPRT) gene (autoradiographic assay in Galveston with slide review in Burlington; cloning assay in Leiden with mutational spectra determined in Burlington); and * chromosomal aberrations by the conventional method and by fluorescence in situ hybridization [FISH]), and cytogenetic changes (sister chromatid exchanges [SCEs] (Prague). All assay analysts were blinded to worker and sample identity and remained so until all work in that laboratory had been completed and reported. Assay results were sent to the Biometry Facility in Burlington for statistical analyses. Analysis of questionnaire data revealed that the three exposure groups were balanced with respect to age and years of residence in the district, but the control group had significantly more education than the other two groups and included fewer smokers. Group average BD exposures were 0.023 mg/m3 (0.010 ppm) for the control group, 0.642 mg/m3 (0.290 ppm) for the monomer group, and 1.794 mg/m3 (0.812 ppm) for the polymer group; exposure levels showed considerable variability between and within individuals. Styrene exposures were significantly higher in the polymer group than in the other two groups. We found no statistically significant differences in the distributions of metabolic genotypes over the three exposure groups; genotype frequencies were consistent with those previously reported for this ethnic and national population. Although some specific genotypes were associated with quantitative differences in urinary metabolite concentrations or Hb adduct dose-response characteristics, none indicated a heightened susceptibility to BD. Concentrations of both the M2 and M1 urinary metabolites and both the HBVal and THBVal Hb adducts were significantly correlated with group and individual mean BD exposure levels; the Hb adducts were more strongly correlated than the urinary metabolites. By contrast, no significant relations were observed between BD exposures and HPRT gene mutations (whether determined by the auto-radiographic or the cloning method) or any of the cytogenetic biomarkers (whether determined by the conventional method or FISH analysis). Neither the mutational nor the cytogenetic responses showed any association with genotypes. The molecular spectrum of HPRT mutations in BD-exposed workers showed a high frequency of deletions; but the same result was found in the unexposed control subjects, which suggests that these were not due to BD exposure. This lack of association between BD exposures and genetic effects persisted even when control subjects were excluded from the analyses or when we conducted regression analyses of individual workers exposed to different levels of BD.
650    _2
$a zvířata $7 D000818
650    _2
$a benzen $x analýza $x metabolismus $7 D001554
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a butadieny $x krev $x metabolismus $x moč $7 D002070
650    _2
$a genotyp $7 D005838
650    _2
$a hemoglobiny $x účinky léků $7 D006454
650    _2
$a lidé $7 D006801
650    _2
$a hypoxanthinfosforibosyltransferasa $x genetika $7 D007041
650    _2
$a průmysl $7 D007221
650    _2
$a lymfocyty $x ultrastruktura $7 D008214
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    _2
$a pracovní expozice $x analýza $x statistika a číselné údaje $7 D016273
650    _2
$a polymorfismus genetický $7 D011110
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a styren $x analýza $x metabolismus $7 D020058
650    _2
$a toluen $x analýza $x metabolismus $7 D014050
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
655    _2
$a Research Support, U.S. Gov't, P.H.S. $7 D013487
700    1_
$a Srám, Radim J
700    1_
$a Vacek, Pamela M
700    1_
$a Lynch, Jeremiah
700    1_
$a Nicklas, Janice A
700    1_
$a van Sittert, Nico J
700    1_
$a Boogaard, Peter J
700    1_
$a Henderson, Rogene F
700    1_
$a Swenberg, James A
700    1_
$a Tates, Ad D
700    1_
$a Ward, Jonathan B
700    1_
$a Wright, Michael
700    1_
$a Ammenheuser, Marinel M
700    1_
$a Binkova, Blanka
700    1_
$a Blackwell, Walter
700    1_
$a de Zwart, Franz A
700    1_
$a Krako, Dean
700    1_
$a Krone, Jennifer
700    1_
$a Megens, Hendricus
700    1_
$a Musilová, Petra
700    1_
$a Rajská, Gabriela
700    1_
$a Ranasinghe, Asoka
700    1_
$a Rosenblatt, Judah I
700    1_
$a Rössner, Pavel
700    1_
$a Rubes, Jiri
700    1_
$a Sullivan, Linda
700    1_
$a Upton, Patricia
700    1_
$a Zwinderman, Ailko H
773    0_
$w MED00204468 $t Research report (Health Effects Institute) $x 1041-5505 $g č. 116 (2003), s. 1-141; discussion 143-162
856    41
$u https://pubmed.ncbi.nlm.nih.gov/12931846 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200911 $b ABA008
991    __
$a 20200915104410 $b ABA008
999    __
$a ok $b bmc $g 1563354 $s 1104066
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2003 $c 116 $d 1-141; discussion 143-162 $e - $i 1041-5505 $m Research report $n Res Rep Health Eff Inst $x MED00204468
GRA    __
$a P30CA22435 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20200911

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...